# Edwards Lifesciences Corp: financial statements, quarterly

EW · NYSE · CIK 1099800 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ew.md) · [Financials](/companies/ew/financials.md) · [Filings](/companies/ew/filings.md) · [Insiders](/companies/ew/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ew/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,243](/filings/0001099800-25-000005.md) | [1,266](/filings/0001099800-25-000005.md) | [1,330](/filings/0001099800-25-000023.md) | [1,369](/filings/0001099800-25-000048.md) | [1,354](/filings/0001099800-25-000062.md) | [1,386](/filings/0001099800-25-000005.md) | [1,413](/filings/0001099800-26-000026.md) | [1,532](/filings/0001099800-26-000043.md) | [1,553](/filings/0001099800-25-000062.md) | [1,570 d](/filings/0001099800-26-000009.md) | [1,649](/filings/0001099800-26-000026.md) | [1,741](/filings/0001099800-26-000043.md) |
| Cost of revenue | $m | [251](/filings/0001099800-24-000086.md) | [251 d](/filings/0001099800-26-000009.md) | [287](/filings/0001099800-25-000023.md) | [276](/filings/0001099800-25-000048.md) | [263](/filings/0001099800-25-000062.md) | [292 d](/filings/0001099800-26-000009.md) | [302](/filings/0001099800-26-000026.md) | [344](/filings/0001099800-26-000043.md) | [345](/filings/0001099800-25-000062.md) | [343 d](/filings/0001099800-26-000009.md) | [363](/filings/0001099800-26-000026.md) | [392](/filings/0001099800-26-000043.md) |
| Gross profit | $m | [993](/filings/0001099800-25-000005.md) | [1,015](/filings/0001099800-25-000005.md) | [1,043](/filings/0001099800-25-000023.md) | [1,094](/filings/0001099800-25-000048.md) | [1,092](/filings/0001099800-25-000062.md) | [1,094](/filings/0001099800-25-000005.md) | [1,111](/filings/0001099800-26-000026.md) | [1,188](/filings/0001099800-26-000043.md) | [1,208](/filings/0001099800-25-000062.md) | [1,227 d](/filings/0001099800-26-000009.md) | [1,286](/filings/0001099800-26-000026.md) | [1,349](/filings/0001099800-26-000043.md) |
| Research and development | $m | [243](/filings/0001099800-24-000086.md) | [242 d](/filings/0001099800-26-000009.md) | [257](/filings/0001099800-25-000023.md) | [272](/filings/0001099800-25-000048.md) | [253](/filings/0001099800-25-000062.md) | [271 d](/filings/0001099800-26-000009.md) | [255](/filings/0001099800-26-000026.md) | [276](/filings/0001099800-26-000043.md) | [281](/filings/0001099800-25-000062.md) | [268 d](/filings/0001099800-26-000009.md) | [263](/filings/0001099800-26-000026.md) | [279](/filings/0001099800-26-000043.md) |
| Selling, general and administrative | $m | [382](/filings/0001099800-24-000086.md) | [417 d](/filings/0001099800-26-000009.md) | [428](/filings/0001099800-25-000023.md) | [448](/filings/0001099800-25-000048.md) | [421](/filings/0001099800-25-000062.md) | [492 d](/filings/0001099800-26-000009.md) | [466](/filings/0001099800-26-000026.md) | [502](/filings/0001099800-26-000043.md) | [515](/filings/0001099800-25-000062.md) | [603 d](/filings/0001099800-26-000009.md) | [522](/filings/0001099800-26-000026.md) | [561](/filings/0001099800-26-000043.md) |
| Operating income | $m | [366](/filings/0001099800-24-000086.md) | [347 d](/filings/0001099800-26-000009.md) | [349](/filings/0001099800-25-000023.md) | [367](/filings/0001099800-25-000048.md) | [351](/filings/0001099800-25-000062.md) | [313 d](/filings/0001099800-26-000009.md) | [395](/filings/0001099800-26-000026.md) | [411](/filings/0001099800-26-000043.md) | [307](/filings/0001099800-25-000062.md) | [151 d](/filings/0001099800-26-000009.md) | [478](/filings/0001099800-26-000026.md) | [513](/filings/0001099800-26-000043.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [52.7](/filings/0001099800-24-000086.md) | [34.1 d](/filings/0001099800-26-000009.md) | [46.3](/filings/0001099800-25-000023.md) | [20.0](/filings/0001099800-25-000048.md) | [40.7](/filings/0001099800-25-000062.md) | [45.1 d](/filings/0001099800-26-000009.md) | [70.3](/filings/0001099800-26-000026.md) | [64.3](/filings/0001099800-26-000043.md) | [56.1](/filings/0001099800-25-000062.md) | [26.2 d](/filings/0001099800-26-000009.md) | [78.3](/filings/0001099800-26-000026.md) | [278](/filings/0001099800-26-000043.md) |
| Net income | $m | [385](/filings/0001099800-25-000005.md) | [370](/filings/0001099800-25-000005.md) | [352](/filings/0001099800-25-000023.md) | [366](/filings/0001099800-25-000048.md) | [3,071](/filings/0001099800-25-000062.md) | [386](/filings/0001099800-25-000005.md) | [358](/filings/0001099800-26-000026.md) | [333](/filings/0001099800-26-000043.md) | [291](/filings/0001099800-25-000062.md) | [91.2 d](/filings/0001099800-26-000009.md) | [381](/filings/0001099800-26-000026.md) | [242](/filings/0001099800-26-000043.md) |
| Diluted EPS | $ per share | [0.63](/filings/0001099800-25-000005.md) | [0.61](/filings/0001099800-25-000005.md) | [0.58](/filings/0001099800-25-000023.md) | [0.61](/filings/0001099800-25-000048.md) | [5.13](/filings/0001099800-25-000062.md) | [0.65](/filings/0001099800-25-000005.md) | [0.61](/filings/0001099800-26-000026.md) | [0.56](/filings/0001099800-26-000043.md) | [0.50](/filings/0001099800-25-000062.md) | not reported | [0.66](/filings/0001099800-26-000026.md) | [0.42](/filings/0001099800-26-000043.md) |
| Basic EPS | $ per share | [0.63](/filings/0001099800-25-000005.md) | [0.61](/filings/0001099800-25-000005.md) | [0.58](/filings/0001099800-25-000023.md) | [0.61](/filings/0001099800-25-000048.md) | [5.14](/filings/0001099800-25-000062.md) | [0.65](/filings/0001099800-25-000005.md) | [0.61](/filings/0001099800-26-000026.md) | [0.57](/filings/0001099800-26-000043.md) | [0.50](/filings/0001099800-25-000062.md) | not reported | [0.66](/filings/0001099800-26-000026.md) | [0.42](/filings/0001099800-26-000043.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [1.4](/filings/0001099800-23-000039.md) | [1.1](/filings/0001099800-25-000005.md) | [1.2](/filings/0001099800-24-000039.md) | [1.6](/filings/0001099800-24-000078.md) | [3.7](/filings/0001099800-24-000086.md) | [3.0](/filings/0001099800-26-000009.md) | [3.1](/filings/0001099800-25-000023.md) | [3.3](/filings/0001099800-25-000048.md) | [2.7](/filings/0001099800-25-000062.md) | [2.9](/filings/0001099800-26-000043.md) | [2.4](/filings/0001099800-26-000026.md) | [2.9](/filings/0001099800-26-000043.md) |
| Current assets | $bn | [4.1](/filings/0001099800-23-000039.md) | [4.0](/filings/0001099800-25-000005.md) | [4.2](/filings/0001099800-24-000039.md) | [4.5](/filings/0001099800-24-000078.md) | [6.7](/filings/0001099800-24-000086.md) | [6.3](/filings/0001099800-26-000009.md) | [6.2](/filings/0001099800-25-000023.md) | [6.6](/filings/0001099800-25-000048.md) | [6.4](/filings/0001099800-25-000062.md) | [6.7](/filings/0001099800-26-000043.md) | [6.2](/filings/0001099800-26-000026.md) | [6.8](/filings/0001099800-26-000043.md) |
| Total assets | $bn | [9.4](/filings/0001099800-23-000039.md) | [9.4](/filings/0001099800-25-000005.md) | [9.7](/filings/0001099800-24-000039.md) | [10.1](/filings/0001099800-24-000078.md) | [13.0](/filings/0001099800-24-000086.md) | [13.1](/filings/0001099800-26-000009.md) | [13.0](/filings/0001099800-25-000023.md) | [13.5](/filings/0001099800-25-000048.md) | [13.3](/filings/0001099800-25-000062.md) | [13.7](/filings/0001099800-26-000043.md) | [13.3](/filings/0001099800-26-000026.md) | [13.9](/filings/0001099800-26-000043.md) |
| Current liabilities | $bn | [1.2](/filings/0001099800-23-000039.md) | [1.2](/filings/0001099800-25-000005.md) | [1.1](/filings/0001099800-24-000039.md) | [1.2](/filings/0001099800-24-000078.md) | [1.9](/filings/0001099800-24-000086.md) | [1.5](/filings/0001099800-26-000009.md) | [1.4](/filings/0001099800-25-000023.md) | [1.4](/filings/0001099800-25-000048.md) | [1.6](/filings/0001099800-25-000062.md) | [1.8](/filings/0001099800-26-000043.md) | [1.4](/filings/0001099800-26-000026.md) | [1.5](/filings/0001099800-26-000043.md) |
| Total liabilities | $bn | [2.6](/filings/0001099800-23-000039.md) | [2.6](/filings/0001099800-25-000005.md) | [2.5](/filings/0001099800-24-000039.md) | [2.6](/filings/0001099800-24-000078.md) | [3.4](/filings/0001099800-24-000086.md) | [3.0](/filings/0001099800-26-000009.md) | [2.8](/filings/0001099800-25-000023.md) | [2.9](/filings/0001099800-25-000048.md) | [3.1](/filings/0001099800-25-000062.md) | [3.4](/filings/0001099800-26-000043.md) | [3.0](/filings/0001099800-26-000026.md) | [3.1](/filings/0001099800-26-000043.md) |
| Long-term debt | $bn | [0.6](/filings/0001099800-23-000039.md) | [0.6](/filings/0001099800-25-000005.md) | [0.6](/filings/0001099800-24-000039.md) | [0.6](/filings/0001099800-24-000078.md) | [0.6](/filings/0001099800-24-000086.md) | [0.6](/filings/0001099800-26-000009.md) | [0.6](/filings/0001099800-25-000023.md) | [0.6](/filings/0001099800-25-000048.md) | [0.6](/filings/0001099800-25-000062.md) | [0.6](/filings/0001099800-26-000043.md) | [0.6](/filings/0001099800-26-000026.md) | [0.6](/filings/0001099800-26-000043.md) |
| Current portion of debt | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $bn | [6.7](/filings/0001099800-23-000039.md) | [6.7](/filings/0001099800-25-000005.md) | [7.1](/filings/0001099800-24-000039.md) | [7.4](/filings/0001099800-24-000078.md) | [9.5](/filings/0001099800-24-000086.md) | [10.0](/filings/0001099800-26-000009.md) | [10.1](/filings/0001099800-25-000023.md) | [10.5](/filings/0001099800-25-000048.md) | [10.2](/filings/0001099800-25-000062.md) | [10.3](/filings/0001099800-26-000043.md) | [10.3](/filings/0001099800-26-000026.md) | [10.6](/filings/0001099800-26-000043.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [412 d](/filings/0001099800-24-000086.md) | [137 d](/filings/0001099800-26-000009.md) | [(53.5)](/filings/0001099800-25-000023.md) | [372 d](/filings/0001099800-25-000048.md) | [352 d](/filings/0001099800-25-000062.md) | [(128) d](/filings/0001099800-26-000009.md) | [280](/filings/0001099800-26-000026.md) | [290 d](/filings/0001099800-26-000043.md) | [574 d](/filings/0001099800-25-000062.md) | [451 d](/filings/0001099800-26-000009.md) | [43.8](/filings/0001099800-26-000026.md) | [652 d](/filings/0001099800-26-000043.md) |
| Capital expenditure | $m | [55.3 d](/filings/0001099800-24-000086.md) | [88.3 d](/filings/0001099800-26-000009.md) | [65.3](/filings/0001099800-25-000023.md) | [85.4 d](/filings/0001099800-25-000048.md) | [51.9 d](/filings/0001099800-25-000062.md) | [49.8 d](/filings/0001099800-26-000009.md) | [56.0](/filings/0001099800-26-000026.md) | [49.3 d](/filings/0001099800-26-000043.md) | [57.5 d](/filings/0001099800-25-000062.md) | [97.4 d](/filings/0001099800-26-000009.md) | [64.9](/filings/0001099800-26-000026.md) | [66.9 d](/filings/0001099800-26-000043.md) |
| Share repurchases | $m | [174 d](/filings/0001099800-24-000086.md) | [448 d](/filings/0001099800-26-000009.md) | [0.2](/filings/0001099800-25-000023.md) | [158 d](/filings/0001099800-25-000048.md) | [901 d](/filings/0001099800-25-000062.md) | [100 d](/filings/0001099800-26-000009.md) | [259](/filings/0001099800-26-000026.md) | [5.5 d](/filings/0001099800-26-000043.md) | [589 d](/filings/0001099800-25-000062.md) | [40.6 d](/filings/0001099800-26-000009.md) | [422](/filings/0001099800-26-000026.md) | [153 d](/filings/0001099800-26-000043.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [625](/filings/0001099800-23-000039.md) | [611](/filings/0001099800-24-000039.md) | [610](/filings/0001099800-24-000078.md) | [610](/filings/0001099800-24-000086.md) | [604](/filings/0001099800-25-000023.md) | [604](/filings/0001099800-25-000048.md) | [598](/filings/0001099800-25-000062.md) | [588](/filings/0001099800-26-000026.md) | [588](/filings/0001099800-26-000043.md) | [586](/filings/0001099800-25-000062.md) | [581](/filings/0001099800-26-000026.md) | [578](/filings/0001099800-26-000043.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 576,400,000 at 2026-07-31, from the cover of the [10-Q filed 2026-08-04](/filings/0001099800-26-000043.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:33 ET. No prices; not investment advice.